Glycemic variability: prognostic impact on acute ischemic stroke and the impact of corrective treatment for hyperglycemia. The GLIAS-III translational study

Autor: Fuentes, Blanca, Pastor-Yborra, Silvia, Gutiérrez-Zúñiga, Raquel, González-Pérez de Villar, Noemí, de Celis, Elena, Rodríguez-Pardo, Jorge, Gómez-de Frutos, Mari Carmen, Laso-García, Fernando, Gutiérrez-Fernández, María, Ortega-Casarrubios, MÁngeles, Soto, Alfonso, López-Fernández, María, Santamaría, María, Díez-González, Noemí, Freijo, Mar M., Zandio, Beatriz, Delgado Mederos, Raquel, Calleja, Ana, Portilla-Cuenca, Juan Carlos, Lisbona, Arturo, Otero-Ortega, Laura, Díez-Tejedor, Exuperio, Universitat Autònoma de Barcelona
Přispěvatelé: UAM. Departamento de Medicina, Instituto de Investigación Sanitaria Hospital Universitario de La Paz (IdiPAZ)
Rok vydání: 2020
Předmět:
Zdroj: Journal of Translational Medicine
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Biblos-e Archivo. Repositorio Institucional de la UAM
Journal of Translational Medicine, Vol 18, Iss 1, Pp 1-8 (2020)
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
ISSN: 1479-5876
2017-3350
Popis: Introduction: Glycemic variability (GV) represents the amplitude of oscillations in glucose levels over time and is associated with higher mortality in critically ill patients. Our aim is to evaluate the impact of GV on acute ischemic stroke (IS) outcomes in humans and explore the impact of two different insulin administration routes on GV in an animal model. Methods: This translational study consists of two studies conducted in parallel: The first study is an observational, multicenter, prospective clinical study in which 340 patients with acute IS will be subcutaneously implanted a sensor to continuously monitor blood glucose levels for 96 h. The second study is a basic experimental study using an animal model (rats) with permanent occlusion of the middle cerebral artery and induced hyperglycemia (through an intraperitoneal injection of nicotinamide and streptozotocin). The animal study will include the following 6 groups (10 animals per group): sham; hyperglycemia without IS; IS without hyperglycemia; IS and hyperglycemia without treatment; IS and hyperglycemia and intravenous insulin; and IS and hyperglycemia and subcutaneous insulin. The endpoint for the first study is mortality at 3 months, while the endpoints for the animal model study are GV, functional recovery and biomarkers. Discussion: The GLIAS-III study will be the first translational approach analyzing the prognostic influence of GV, evaluated by the use of subcutaneous glucose monitors, in acute stroke. Trial registrationhttps://www.clinicaltrials.gov (NCT04001049)
The study is investigator-initiated, promoted and coordinated by the Research Foundation of La Paz University Hospital (Fundación de Investigación del Hospital Universitario La Paz) and funded by a grant (PI18/00991) from the Carlos III Health Institute (ISCIII) Health Care Research Fund and co-funded by the European Regional Development Fund (ERDF). The study is sponsored by the Stroke Project of the Cerebrovascular Diseases Study Group of the Spanish Neurological Society and the INVICTUS-Plus Spanish Network of the ISCIII (RD16/0019/0005). The study is also sponsored by Juan de la Cierva postdoctoral fellowship (IJCI-2017-33505 to Laura Otero-Ortega, Spanish State Research Agency), the Spanish Ministry of Science and Innovation.
Databáze: OpenAIRE
Externí odkaz: